PDCD1 and melanoma: This may be related to the FDA approval of the PD-1 checkpoint drugs (nivolumab and pembrolizumab) for the immunotherapy of NSCLC and melanoma at the end of 2014 (Borghaei et al., 2015; Herbst et al., 2016).